Biota to boost Melbourne facilities
Wednesday, 21 March, 2012
Biota (ASX:BTA) plans to expand its Melbourne facilities, in collaboration with the Victorian government.
The anti-infective drug development company plans to complete the expansion by 2014, to enable it to fulfil the US$231 million ($218.1 million) contract it won last year.
This deal, with the US Office of Biomedical Advanced Research & Development Authority (BARDA) tasks Biota with establishing US manufacturing and work towards FDA approval for its laninamivir influenza antiviral.
Laninamivir is single dose, long-acting neuraminidase inhibitor. The product is already marketed in Japan under the brand name Inavir.
Victoria's Minister for Technology, Gordon Rich-Phillips revealed that the government will support Biota in its efforts to expand the facility.
Rich-Phillips said the expansion will result in the creation of 35 new specialist jobs. Biota currently employs 85 people in Victoria, and also has a presence in the UK.
Biota shares closed Tuesday's trading 0.56% lower at $0.895.
ADHD drug shows promise for treating meth addiction
A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be...
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
